SITTINGBOURNE, England--(BUSINESS WIRE)--Vivacta Limited, the medical diagnostics company with a revolutionary system for point‐of‐care testing, announced today it plans large scale production of its disposable cartridges to meet commercial demand ahead of establishing strategic relationships with commercial partners.
Vivacta’s cartridges incorporate an innovative piezofilm sensor. Vivacta’s technology platform enables the development of next-generation point-of-care diagnostics and monitoring systems. The finger-prick tests provide lab-quality measurement of disease markers and drugs in whole-blood in under ten minutes.
To lead the new initiative, Vivacta has appointed Andrew Whittle as Process Engineering Manager. Mr Whittle was Operations Manager and Site Leader at ThermoFisher Scientificprior to his appointment and brings in-depth knowledge of establishing an IVD (in vitro diagnostics) manufacturing cell to Vivacta.
Dr Tim Carter, CEO, said, "The creation of our pilot facility in 2009 gave Vivacta the strategic advantage of being able to develop new tests on consistently manufactured materials and demonstrated to potential commercial partners the scaleability of our process. Now we see the need to establish executable plans for commercial-scale manufacturing and we are delighted that Andrew Whittle has agreed to join us and lead this effort”.
In recognition of her role in achieving ISO 13485:2003 compliance for Vivacta’s existing pilot facility and the importance of her work in quality management, Sonja Jones has been promoted to Director of Quality and Regulatory Affairs.
About Vivacta
Vivacta Limited is applying its expertise in piezofilm technology to develop a range of new generation high performance PoC diagnostics able to deliver quantitative readings within 10 minutes from a single pin prick of blood.
The Company’s platform technology exploits the piezoelectric effect by which thermal perturbations on a piezofilm surface cause an electric charge to be produced. The measurement of this electric charge enables monitoring of chemical activity – or rate of binding between antibody and analyte – in an assay. In harnessing this piezofilm platform technology, Vivacta has developed PoC diagnostic products able to produce and present sensitive, precise and fully quantitative results, equivalent to those produced in laboratories.
Each test requires only a finger prick sample, providing actionable results in 10 minutes or less. Rapid point-of-care testing avoids the delay caused by sending samples away to a remote laboratory for analysis and is essential where speed of diagnosis or frequent testing (monitoring) is medically necessary or economically desirable.
Vivacta has generated an independent intellectual property position of over 10 patent families protecting the use of piezofilms in diagnostic assays. Vivacta’s investors include Albion Ventures, HBM BioVentures, IDInvest (formerly AGF), Spark Ventures and Viking.
For more information please visit www.vivacta.com